Medsafe Of New Zealand Cites U.S. FDA In Safety Defense Of Pradaxa
This article was originally published in PharmAsia News
New Zealand's regulatory agency Medsafe sought to defend itself against safety questions raised over its approval of Boehringer Ingelheim's Pradaxa (dabigatran) for preventing blood clots in surgery by noting that it had access to the same clinical trial data required by U.S. FDA, which also approved the drug
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.